Human Proteinase 3 (PR3) ELISA Kit
Proteinase 3 (PR3), also known as myeloblastin, azurophil granule protein-7 or p29b, PRTN3 and NP- 4, is one of the hematopoietic serine proteases localized in the primary granules of polymorphonuclear neutrophils (PMNs). It is a 29kDa glycoprotein made of 222 amino acids and is released during neutrophilic inflammation.
PRINCIPLE OF THE ASSAY
This assay is a quantitative sandwich ELISA. The microtiter strips are pre-coated with a polyclonal antibody specific for human PR3. Standards and samples are pipetted into the wells and any human PR3 present is bound by the immobilized antibody. After washing away any unbound substances, a horseradish peroxidise (HRP) labelled polyclonal antibody specific for human PR3 is added to the wells. After wash step to remove any unbound reagents, an HRP substrate solution is added and colour develops in proportion to the amount of human PR3 bound initially. The assay is stopped and the optical density of the wells is determined using a micro-plate reader. Since the increase in absorbance is directly proportional to the amount of captured human PR3, the unknown sample concentration can be interpolated from a reference curve included in each assay.
A. Typical representation of standard curve
The following standard curve is provided for demonstration only. A standard curve should be generated for each set of sample assay.
Absorbance (450 nm)
PUBLICATIONS CITING THIS PRODUCT
- Elie AG, Bloksgaard M, Sun WY, Yang K, Man AW, Xu A, Irmukhamedov A, Riber LP, Wang Y, De Mey JG. Local enrichment of fatty acid-binding protein 4 in the pericardial cavity of cardiovascular disease patients. PloS one. 2018 Nov 5;13(11):e0206802.
- Ong KL, Wu L, Januszewski AS, O’Connell R, Xu A, Scott RS, Sullivan DR, Rye KA, Li H, Ma RC, Li L. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diabetes and Vascular Disease Research. 2021 Jul;18(4):14791641211032547.